Quick Answer
Mazdutide is a once-weekly injectable dual GLP-1/glucagon receptor agonist co-developed by Innovent Biologics and Eli Lilly. Phase 3 trials in China showed up to 18.6% body weight loss at the 6 mg dose over 48 weeks. It is already approved in China under the brand name MaZhuDa for chronic weight management. It is not FDA-approved and not available in the US.
How Mazdutide Works
Mazdutide targets two receptors at once, which is why it is called a dual agonist:
- GLP-1 receptor — Reduces appetite, slows digestion, and improves blood sugar control. This is the same mechanism as Ozempic (semaglutide) and Wegovy.
- Glucagon receptor — Increases energy expenditure and fat oxidation. Glucagon normally raises blood sugar, but at therapeutic doses it also increases how many calories your body burns.
The combination means mazdutide attacks weight from two directions: less food intake (GLP-1) and more calories burned (glucagon). This is the same dual-agonist concept behind survodutide, another investigational drug from a different company.
Weight Loss Results
Phase 2 trial (DREAM-1):
The Phase 2 DREAM-1 trial tested mazdutide in Chinese adults with obesity. Results:
| Dose | Weight Loss (24 weeks) |
|---|---|
| 2 mg | ~8.5% |
| 4 mg | ~11.6% |
| 6 mg | ~14.7% |
Phase 3 trial (DREAM-3):
The Phase 3 DREAM-3 trial enrolled Chinese adults with obesity (BMI ≥28) without type 2 diabetes. Key results at 48 weeks:
| Dose | Weight Loss |
|---|---|
| 6 mg | 18.6% |
| 4 mg | ~15% |
Additional findings:
- Over 80% of participants on 6 mg lost at least 5% of body weight
- Over 60% lost at least 15% of body weight
- Waist circumference decreased significantly
- Blood pressure and lipid markers improved
These results are in the same range as Zepbound (tirzepatide, ~20-21% in SURMOUNT trials) and exceed what Wegovy (semaglutide, ~15%) achieved in comparable trials.
Important caveat on trial comparisons
These numbers come from trials conducted in Chinese populations, which can differ from Western populations in average BMI, body composition, and metabolic profile. Cross-trial comparisons are not head-to-head studies. The results are promising but should be interpreted with that context.
What Else Mazdutide May Treat
Beyond obesity, mazdutide is being studied for:
- Type 2 diabetes — Phase 3 DREAM-2 trial in Chinese adults with T2D showed significant HbA1c reductions and weight loss
- MASLD/MASH (fatty liver disease) — The glucagon mechanism may reduce liver fat, similar to what was seen with survodutide. Trials are ongoing
- Cardiovascular risk reduction — Exploratory, no Phase 3 data yet
The glucagon component is of particular interest for liver disease because glucagon agonism directly targets hepatic fat metabolism — something GLP-1-only and GLP-1/GIP drugs do less effectively.
China Approval
Mazdutide was approved by China's National Medical Products Administration (NMPA) in 2024 for chronic weight management in adults with obesity (BMI ≥28) or overweight (BMI ≥24) with at least one weight-related comorbidity. It is marketed in China under the brand name MaZhuDa.
This makes mazdutide one of the first GLP-1/glucagon dual agonists approved anywhere in the world for obesity, alongside a small number of other drugs in this class.
Side Effects
Side effects reported in Phase 2 and Phase 3 trials are consistent with other GLP-1 medications:
- Nausea — Most common, especially during dose escalation
- Vomiting
- Diarrhea
- Constipation
- Abdominal pain
The glucagon component does not appear to cause significantly different side effects compared to GLP-1-only drugs like Ozempic or Wegovy. Gastrointestinal symptoms tend to be most common during the first few weeks and improve over time.
In Phase 3 trials, discontinuation rates due to side effects were in the range of 5-10%, which is comparable to other GLP-1 medications.
How It Compares
| Feature | Mazdutide | Ozempic/Wegovy | Mounjaro/Zepbound | Survodutide | Retatrutide |
|---|---|---|---|---|---|
| Mechanism | GLP-1 + glucagon | GLP-1 only | GLP-1 + GIP | GLP-1 + glucagon | GLP-1 + GIP + glucagon |
| Max weight loss (trials) | ~18.6% | ~15% | ~20-21% | ~19% | ~28.3% |
| Dosing | Weekly injection | Weekly injection | Weekly injection | Weekly injection | Weekly injection |
| Approved anywhere | China only | US and global | US and global | No | No |
| Available in US | No | Yes | Yes | No | No |
Key differences:
- Mazdutide vs Wegovy/Ozempic: Dual agonism (GLP-1 + glucagon) vs single (GLP-1 only). Mazdutide shows higher weight loss in its trials.
- Mazdutide vs Zepbound: Both are dual agonists but target different second receptors. Zepbound targets GIP; mazdutide targets glucagon. Zepbound shows slightly higher weight loss and is available now.
- Mazdutide vs Survodutide: Same dual mechanism (GLP-1 + glucagon), different companies. Mazdutide is ahead in approvals (China); survodutide has stronger MASH data. Neither is available in the US.
- Mazdutide vs Retatrutide: Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) showing the highest weight loss numbers in trials (~28.3%), but is not approved anywhere yet.
When Could It Be Available in the US?
As of June 2026, there is no confirmed timeline for mazdutide's FDA submission or US availability. What we know:
- China approval: Already approved and available as MaZhuDa
- Global development: Eli Lilly and Innovent have discussed plans for global Phase 3 trials, but these have not been formally launched in the US or Europe
- FDA submission: Could happen as early as 2027-2028 if global trials begin soon, but this is speculative
- Earliest possible US availability: 2028-2029 at the earliest, assuming global trials proceed on schedule
This timeline is optimistic. Drug development often takes longer than expected, and the regulatory pathway for a drug already approved in China may not be straightforward for the US market.
Should You Wait for Mazdutide?
No. If you need help with weight management now, there are multiple FDA-approved options available today:
- Wegovy (semaglutide) — up to ~15% weight loss
- Zepbound (tirzepatide) — up to ~21% weight loss
- Foundayo (orforglipron) — daily pill, no needles
Waiting years for an experimental drug that may or may not be better is not a good strategy when effective treatments already exist. If mazdutide turns out to offer meaningful advantages, switching later is always an option.
Bottom Line
Mazdutide is a promising GLP-1/glucagon dual agonist with strong Phase 3 weight loss data and the distinction of being the first drug in its class approved for obesity (in China). But it is not available in the US, and the timeline for global availability is uncertain.
If you are tracking the next generation of GLP-1 drugs, mazdutide joins survodutide, retatrutide, VK2735, and CagriSema as drugs to watch — but none of them should replace starting treatment with what works today.
If you are currently on a GLP-1 injection, basic supplies like alcohol prep pads and a sharps container are essentials. A protein powder can help you hit protein goals while your appetite adjusts.
GLPSpot may earn from qualifying purchases.
This article is for informational purposes only and does not constitute medical advice. Mazdutide is not FDA-approved in the United States. Always talk to your healthcare provider before starting or changing any medication.
